Previous 10 | Next 10 |
CUPERTINO, Calif. , March 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient enrollment in a Phase 1b trial with oral DUR-928 in patients with NASH. DUR-928, the lead investigational product in the Company's Epigenetic Regulator Pro...
DURECT Corporation (NASDAQ: DRRX ) has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis. More news on: DURECT Corporation, Healthcare stocks news, Read more ...
CUPERTINO, Calif. , March 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis. DUR-928, the lead investigational produc...
Market Assessment In Q1/2019, DUR-928, the lead investigative drug candidate for Durect ( DRRX ), joins the list of more than 30 drug candidates in clinical development for NASH in 2019. As an early stage test drug candidate, DUR-928 is still a few years away from demonstrating its poten...
DURECT Corporation (DRRX) Q4 2018 Earnings Conference Call March 7, 2019 16:30 ET Company Participants Mike Arenberg - Chief Financial Officer Jim Brown - President and Chief Executive Officer Conference Call Participants François Brisebois - Laidlaw & Company Neil...
Durect ( DRRX ) Q4 results : Revenues: $3.6M (-81.5%); Collaborative R&D and other revenue: $0.8M (-95.1%); Product revenue: $2.9M (-12.1%). More news on: Durect Corporation, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Durect (NASDAQ: DRRX ): Q4 GAAP EPS of -$0.05 in-line. More news on: Durect Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
CUPERTINO, Calif. , March 7, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2018 and provided a corporate update. Total revenues were $3.6 million and net loss was $7.3 million ...
CUPERTINO, Calif. , March 4, 2019 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 7, 2019 at ...
CUPERTINO, Calif. , Feb. 27, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has completed a comprehensive review of its POSIMIR ® (bupivacaine extended-release solution) program and plans to submit a full response to the Complete Response Letter (CRL)...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...